# Tempus AI Shares Jump 30% After Morgan Stanley Revenue Boost

> Morgan Stanley's revenue outlook boost lifts Tempus AI shares 30% this week.
- Title: Tempus AI Shares Jump 30% After Morgan Stanley Revenue Boost
- Summary: Morgan Stanley's revenue outlook boost lifts Tempus AI shares 30% this week. Morgan Stanley's revised revenue projections for Tempus AI's diagnostics…
- Keywords: tempus ai, morgan stanley, revenue outlook, diagnostics, xt diagnostics, xf diagnostics, astra zeneca, gsk, merck, personalis, nfl, seahawks
- Source: Yahoo Finance — https://finance.yahoo.com/markets/stocks/articles/tempus-ai-ripping-30-higher-154733359.html
- Published: 2026-09-17T15:47:33+00:00
- Read time: 1 min
- Topics: tempus ai, morgan stanley, revenue outlook, diagnostics, xt diagnostics, xf diagnostics, astra zeneca, gsk, merck, personalis, nfl, seahawks
## Tempus AI Shares Surge
Tempus AI shares rose 30% this week after Morgan Stanley highlighted reimbursement pricing that could add $330 million to $400 million in annual revenue across xT and xF diagnostics.
## CEO Lefkofsky Projects Growth
CEO Eric Lefkofsky stated Tempus will exceed its 25% multiyear growth target, with $200 million in Q2 data licensing bookings from AstraZeneca, GSK, and Merck.
## Revenue Projections
Morgan Stanley estimates xT pricing adds $80 million to $100 million next year, while xF approval and pricing could add $250 million to $300 million annually.
## Market Reaction
Shares trade at 9x sales, below their 52-week high of $104.32 despite a 54.24% one-month gain, with the $68.18 analyst target lagging the market price.
## Q2 Data Licensing
Q2 revenue reached $382.49 million, up 21.6% year over year, with oncology testing volumes accelerating 31%.
## Analyst Sentiment Shift
Forward EPS estimates for fiscal 2027 have swung from -$0.1067 ninety days ago to $0.0040 today, with eight upward revisions in the past 30 days.
## What's Next
Tempus AI's reimbursement clarity and pending Personalis deal could drive positive free cash flow by year end, despite ongoing GAAP losses and high stock-based compensation.
## Key takeaway

Morgan Stanley's revised revenue projections for Tempus AI's diagnostics services boosted shares 30% this week, with $330M to $400M in annual revenue potential.